Krajina: Austrália
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
bosentan monohydrate, Quantity: 64.541 mg
Sun Pharma ANZ Pty Ltd
bosentan monohydrate
Tablet, film coated
Excipient Ingredients: glycerol dibehenate; povidone; pregelatinised maize starch; sodium starch glycollate type A; magnesium stearate; maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose
Oral
60, 56
(S4) Prescription Only Medicine
Bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including Eisenmenger?s physiology,in patients with WHO functional Class II, III or IV symptoms
Visual Identification: The 62.5mg film-coated tablets are light peach to peach colored, round shaped, biconvex & debossed with '62.5' on one side & plain on the other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2016-07-11